Close
Nordic 9Nordic 9

Brook Byers (investor - Angel Investor)

United States
See something wrong or missing? Let us know
Offices:San Francisco

Brook Byers is a senior partner at Kleiner Perkins and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.

Average round investment:47.64M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: Netherlands Leyden Labs
Mostly invests in: Netherlands Netherlands (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Brook Byers

Name Criteria
United States Casdin Capital
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy Panakès Partners
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Thuja Capital Management B.V.
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands LSP (Life Sciences Partners)
67%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United States Tekla Capital Management
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland Essential Investments
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Green Sands Equity
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Medicxi
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden AP4 - Fjärde AP-fonden
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Hong Kong CR-CP Life Science Fund
66%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top